RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Un modello di progressione neoplastica per il carcinoma del cavo orale: studio genomico e proteomico in vivo ed in vivo di linee cellulari e subcloni ad elevata aggressività. Correlazioni con la progressione neoplastica.
• 2 - Meccanismi molecolari di carcinogenesi: validazione di nuovi bersagli per la diagnosi e la terapia
• 3 - Sviluppo e progressione del carcinoma epatocellulare: meccanismi molecolari ed implicazioni terapeutiche
• 4 - Studio dei meccanismi molecolari alla base dell’anomala proliferazione e funzione paratiroidea, e identificazione ed uso clinico di marcatori molecolari di carcinoma paratiroideo sporadico e familiare. Nuove acquisizione sulla prevalenza delle manifestazioni scheletriche, neuropsichiche e metaboliche dell’iperparatiroidismo primario, loro relazione con i polimorfismi del recettore del calcio ed effetti della paratiroidectomia.
• 5 - Studio delle alterazioni molecolari e funzionali in lesioni preneoplastiche e neoplastiche epatiche con diversa capacità di progressione. Individuazione di nuovi marcatori diagnostici e prognostici e bersagli terapeutici
• 6 - Studio delle alterazioni biomolecolari e dei profili di espressione genica nel carcinoma colorettale e pancreatico: identificazione di possibili elementi prognostici e bersagli terapeutici nel sistema degli eicosanoidi e dei cannabinoidi.
• 7 - Medulloblastoma: studio delle vie molecolari di sviluppo e progressione tumorale allo scopo di identificare approcci terapeutici innovativi
• 8 - I carcinomi in situ aggressivi della mammella. Caratteristiche strutturali, geniche e prospettive terapeutiche.
• 9 - Marcatori molecolari nella tumorigenesi epatica nell'uomo e nell'animale da esperimento.
• 10 - Caratterizzazione molecolare dell'eritropoiesi:analisi post-genomica e funzionale del profilo di espressione proteica

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • ANATOMIA PATOLOGICA
  • MALATTIE ODONTOSTOMATOLOGICHE

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q)

Classificazione geografica

• Regione: Marche

Bibliografia

1 Thompson CB (1995) Apoptosis in the pathogenesis and treatment of disease. Science 267:1456-62
2 Reed JC (1998) Bcl-2 family proteins. Oncogene 17:3225-36
3 LaCasse EC et al (1998) The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17:3247-59
4 Vaux DL et al (1988) Bcl-2 gene promotes haemopoietic cell survival and cooperates with c- myc to immortalize pre-B cells. Nature 335:440-2
5 Ambrosini G et al (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917-21
6 Tamm I et al (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58:5315-20
7 Adida C et al (1998) Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 351:882-3
8 Lu CD et al (1998) Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 58:1808-12
9 Kawasaki H et al (1998) Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58:5071-4
10 Lo Muzio L et al (2001) Expression of the apoptosis inhibitor survivin in aggressive squamous cell carcinoma. Exp Mol Pathol 70:249-54.
11 Tanaka C et al. (2003). Expression of an inhibitor of apoptosis, survivin, in oral carcinogenesis. J Dent Res 82:607-11.
12 Lo Muzio L et. (2003). Survivin expression in oral squamous cell carcinoma. Br J Cancer 89:2244-2248.
13 Chiodino C et al. (1999). Communication: expression of the novel inhibitor of apoptosis survivin in normal and neoplastic skin. J Invest Dermatol 113:415-8.
14 Grossman D et al. (1999). Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab Invest 79:1121-6.
15 Altieri DC (2001). Themolecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 7:542-7.
16 Li F et al. (1998). Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580-4.
17 Hoffman WH et al (2002). Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277:3247-57.
18 Mirza A et al (2002). Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21:2613-22.
19. Zhou M et al (2002). DNA Damage Induces a Novel p53-Survivin Signaling Pathway Regulating Cell Cycle and Apoptosis in Acute Lymphoblastic Leukemia Cells. J Pharmacol Exp Ther 303:124-31
20. Hanahan D, Weinberg RA (2000). The hallmarks of cancer. Cell 100:57-70.
21. Lo Muzio L et. (2003). Survivin, a potential early predictor of tumor progression in the oral mucosa. J Dent Res. 82:923-8
22 Verhagen AM, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell. 2000; 102:43-53.
23 Chai J, et al. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 2000; 406:855-62.
24 Yoo NJ et al. Immunohistochemical analysis of Smac/DIABLO expression in human carcinomas and sarcomas. Apmis 2003; 111:382-8
25 Reichert TE et al: Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 2002; 8:3137-3145.
26. Gumbiner BM et al (1993) Catenins as mediators of the cytoplasmic functions of cadherins. J Cell Sci Suppl 17:155-8
27. Tao YS et al (1996) beta-Catenin associates with the actin-bundling protein fascin in a noncadherin complex. J Cell Biol 1996; 134:1271-81
28. Sommers CL et al (1994) Alterations in beta-catenin phosphorylation and plakoglobin expression in human breast cancer cells. Cancer Res 54:3544-52
29. Rimm DL et al (1995) Reduced alpha-catenin and E-cadherin expression in breast cancer. Lab Invest 72:506-12
30. Valizadeh A et al (1997) Expression of E-cadherin-associated molecules (alpha-, beta-, and gamma- catenins and p120) in colorectal polyps. Am J Pathol 150:1977-84
31. Takayama T et al (1996) Beta-catenin expression in human cancers. Am J Pathol 148:39-46
32. Lo Muzio L et al (1999) Beta- and Gamma-Catenin Expression in Oral Squamous Cell Carcinomas. Anticancer Res 19:3817-26
33. Lo Muzio L (2001) A Possible Role for the WNT-1 Pathway in Oral Carcinogenesis. Crit Rev Oral Biol Med 12:152-165
34. Chow V et al (2001) A comparative study of the clinicopathological significance of E-cadherin and catenins (alpha, beta, gamma) expression in the surgical management of oral tongue carcinoma. J Cancer Res Clin Oncol. 127:59-63
35. Yost C et al (1996) The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 10:1443-54
36. Rubinfeld B et al (1997) Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 275:1790-2
37. Peifer M (1997) Beta-catenin as oncogene: the smoking gun. Science 275:1752-3
38. Behrens J et al (1996) Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 382:638-42
39. Aoki M et al (1999) Nuclear endpoint of Wnt signaling: Neoplastic transformation induced by transactivating lymphoid-enhancing factor 1. PNAS 96:139-144
40. Young CS et al (1998) Wnt-1 induces growth, cytosolic beta-catenin, and Tcf/Lef transcriptional activation in Rat-1 fibroblasts. Mol Cell Biol 18:2474-85
41. Huber O et al (1996) Nuclear localization of beta-catenin by interaction with transcription factor LEF-1. Mech Dev 59:3-10
42. Shtutman M et al (1999) The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. PNAS 96:5522-7
43. Tetsu O et al (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422-6
44. He T-C et al (1998) Identification of c-MYC as a Target of the APC Pathway. Science 281:1509-1512
45. Mann B et al (1999) Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. PNAS 96:1603-8
46. Werkmeister R et al (2000) Clinical relevance of erbB-1 and -2 oncogenes in oral carcinomas. Oral Oncol 36:100-5
47. Moon HS et al (2001) Expression and tyrosine phosphorylation of E-cadherin, beta- and gamma-catenin, and epidermal growth factor receptor in cervical cancer cells. Gynecol Oncol 81:355-9
48. Al Moustafa AE et al (2002) Regulation of E-cadherin/catenin complex patterns by epidermal growth factor receptor modulation in human lung cancer cells. Lung Cancer 37:49-56
49. Bankfalvi A et al (2002) Deranged expression of the E-cadherin/beta-catenin complex and the epidermal growth factor receptor in the clinical evolution and progression of oral squamous cell carcinomas. J Oral Pathol Med 31:450-7
50. Warnakulasuriya S (2000) Lack of molecular markers to predict malignant potential of oral precancer. J Pathol 190:407-9
51. Pindborg JJ et al (1977) A follow-up study of sixty-one oral dysplastic precancerous lesions in Indian villagers. Oral Surg Oral Med Oral Pathol 43:383-90
52. Silverman S et al (1984) Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer 53:563-8
53. Oliver RJ et al (2000) Comparison of BrdU and cyclin A as markers of the S-phase in oral precancerous lesions. J Oral Pathol Med 29:426-31
54. Oliver RJ et al (2000) Aspects of cell proliferation in oral epithelial dysplastic lesions. J Oral Pathol Med 29:49-55
55. Soukos NS et al(2001) Epidermal growth factor receptor-targeted immunophotodiagnosis and photoimmunotherapy of oral precancer in vivo. Cancer Res 61:4490-6
56. Wilkman TS et al(1998) Immunohistochemicalanalysis of the oncoprotein c-erbB-2 expression in oral benign and malignant lesions. Int J Oral Maxillofac Surg 27:209-12
57. Hou L et al (1992) Oral cancer progression and c-erbB-2/neu proto-oncogene expression. Cancer Lett 65:215-20
58. Tanimoto K et al (2000) Abnormalities of the FHIT gene in human oral carcinogenesis. Br J Cancer 82:838-43

Parole Chiave

CARCINOMA ORALE; LESIONI PRECANCEROSE; APOPTOSI; ADESIONE; FATTORI DI CRESCITA; SURVIVINA; SMAC/DIABLO; CATENINE; FAS/FASL